<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04518046</url>
  </required_header>
  <id_info>
    <org_study_id>516-008</org_study_id>
    <nct_id>NCT04518046</nct_id>
  </id_info>
  <brief_title>Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies</brief_title>
  <official_title>A Phase 1/1b Study of Sitravatinib in Combination With Nivolumab and Ipilimumab in Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mirati Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mirati Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study 516-008 is an open-label Phase 1 dose escalation/Phase 1b dose expansion study&#xD;
      evaluating the safety and tolerability, clinical activity, and PK of sitravatinib in&#xD;
      combination with nivolumab and ipilimumab for the treatment of ccRCC and potentially other&#xD;
      solid tumor types.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that inhibits&#xD;
      several closely related RTKs including the TAM family (Tyro3/Axl/MERTK), VEGFR2, KIT, and&#xD;
      MET.&#xD;
&#xD;
      NIVO/IPI are monoclonal antibodies (mAbs) that inhibit the immune checkpoint proteins&#xD;
      programmed death receptor-1 (PD-1) and cytotoxic T- lymphocyte antigen-4 (CTLA-4),&#xD;
      respectively.&#xD;
&#xD;
      The current study is designed to evaluate the triple combination of sitravatinib plus&#xD;
      NIVO/IPI in patients with solid tumor malignancies that have shown favorable responses to&#xD;
      NIVO/IPI combinations in previous clinical trials. Combining sitravatinib and NIVO/IPI is&#xD;
      predicted to have complementary effects in triggering a tumor-directed immune response.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 11, 2020</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Following the identification of the recommended dose of sitravatinib in combination with NIVO/IPI Phase 1 dose escalation, two Phase 1b dose expansion cohorts will enroll patients with ccRCC based on IMDC risk. All patients receive the same treatment.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of patients experiencing treatment-emergent AEs</measure>
    <time_frame>Through study completion, an average of 12 months</time_frame>
    <description>Characterization of AEs by incidence, severity, timing, seriousness &amp; relationship to study treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) in accordance with RECIST v1.1</measure>
    <time_frame>Through duration of study, average of 10 months</time_frame>
    <description>Frequency of patients experiencing an objective response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Through duration of study, average of 10 months</time_frame>
    <description>Time in months from date of the first documentation of objective tumor response (CR or PR) to the first documentation of objective PD or to death due to any cause in the absence of documented PD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>Through duration of study, average of 10 months</time_frame>
    <description>Time from date of first study treatment to first PD or death due to any cause in the absence of documented PD</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">92</enrollment>
  <condition>Clear-Cell Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Phase 1: Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with poor- or intermediate-risk RCC with clear cell component for first-line treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b Dose Escalation Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with poor- or intermediate-risk RCC with clear cell component for first-line treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b Dose Escalation Cohort B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with favorable-risk RCC with clear cell component for first-line treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitravatinib</intervention_name>
    <description>Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases</description>
    <arm_group_label>Phase 1: Dose Escalation</arm_group_label>
    <arm_group_label>Phase 1b Dose Escalation Cohort A</arm_group_label>
    <arm_group_label>Phase 1b Dose Escalation Cohort B</arm_group_label>
    <other_name>MGCD516</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody</description>
    <arm_group_label>Phase 1: Dose Escalation</arm_group_label>
    <arm_group_label>Phase 1b Dose Escalation Cohort A</arm_group_label>
    <arm_group_label>Phase 1b Dose Escalation Cohort B</arm_group_label>
    <other_name>OPDIVO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>Ipilimumab is a CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) blocking antibody</description>
    <arm_group_label>Phase 1: Dose Escalation</arm_group_label>
    <arm_group_label>Phase 1b Dose Escalation Cohort A</arm_group_label>
    <arm_group_label>Phase 1b Dose Escalation Cohort B</arm_group_label>
    <other_name>YERVOY</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed diagnosis of Clear-Cell Renal Cell Carcinoma (for initial cohorts under&#xD;
             consideration)&#xD;
&#xD;
          -  No prior treatment with systemic therapy (for initial cohorts under consideration)&#xD;
&#xD;
          -  Adequate bone marrow and organ function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known or suspected presence of other cancer&#xD;
&#xD;
          -  Brain metastases (for initial cohorts under consideration)&#xD;
&#xD;
          -  Carcinomatous meningitis&#xD;
&#xD;
          -  Immunocompromising conditions&#xD;
&#xD;
          -  Impaired heart function&#xD;
&#xD;
          -  Active or prior documented autoimmune disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hirak Der-Torossian, MD</last_name>
    <role>Study Director</role>
    <affiliation>Mirati Therapeutics Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mirati Therapeutics Study Locator Services</last_name>
    <phone>18448935530</phone>
    <email>miratistudylocator@emergingmed.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>MD Anderson</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>August 3, 2020</study_first_submitted>
  <study_first_submitted_qc>August 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2020</study_first_posted>
  <last_update_submitted>December 18, 2020</last_update_submitted>
  <last_update_submitted_qc>December 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

